OraSure Technologies (NASDAQ:OSUR) Rating Lowered to Hold at StockNews.com

OraSure Technologies (NASDAQ:OSUR) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other equities analysts have also recently issued reports on OSUR. Evercore ISI raised their price objective on OraSure Technologies from $4.50 to $5.00 and gave the stock an “in-line” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. reduced their price target on shares of OraSure Technologies from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Monday, May 13th. Three investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $6.67.

OraSure Technologies Stock Up 1.5 %

Shares of OraSure Technologies stock opened at $4.18 on Friday. The business has a 50-day moving average price of $4.29 and a 200 day moving average price of $5.41. OraSure Technologies has a fifty-two week low of $3.91 and a fifty-two week high of $8.45. The firm has a market cap of $309.15 million, a P/E ratio of 13.93 and a beta of 0.09.

Institutional Investors Weigh In On OraSure Technologies

Large investors have recently added to or reduced their stakes in the stock. Tocqueville Asset Management L.P. raised its position in shares of OraSure Technologies by 20.0% during the 1st quarter. Tocqueville Asset Management L.P. now owns 15,089 shares of the medical instruments supplier’s stock worth $93,000 after buying an additional 2,512 shares in the last quarter. AXA S.A. boosted its stake in OraSure Technologies by 2.5% during the 2nd quarter. AXA S.A. now owns 161,614 shares of the medical instruments supplier’s stock valued at $688,000 after purchasing an additional 3,997 shares in the last quarter. AJOVista LLC bought a new position in OraSure Technologies during the 4th quarter valued at $39,000. SG Americas Securities LLC increased its position in shares of OraSure Technologies by 46.4% during the 2nd quarter. SG Americas Securities LLC now owns 17,125 shares of the medical instruments supplier’s stock valued at $73,000 after purchasing an additional 5,431 shares during the period. Finally, Lazard Asset Management LLC lifted its holdings in shares of OraSure Technologies by 12.9% in the first quarter. Lazard Asset Management LLC now owns 56,908 shares of the medical instruments supplier’s stock valued at $349,000 after buying an additional 6,500 shares during the period. 93.50% of the stock is owned by institutional investors and hedge funds.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.